Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project

Abstract

Background The ABC (age, biomarkers, and clinical history)-stroke and ABC-bleeding are biomarker-based scores proposed to predict stroke and bleeding, but non-specificity of biomarkers is common, predicting different clinical events at the same time. We assessed the predictive performance of the ABC-stroke and ABC-bleeding scores, for outcomes beyond ischemic stroke and major bleeding, in a cohort of atrial fibrillation (AF) patients. Methods We included AF patients stable on vitamin K antagonists for 6 months. The ABC-stroke and ABC-bleeding were calculated and the predictive values for myocardial infarction (MI), acute heart failure (HF), a composite of cardiovascular events, and all-cause deaths were compared. Results We included 1,044 patients (49.2% male; median age 76 [71–81] years). During 6.5 (4.3–7.9) years, there were 58 (5.6%) MIs, 98 (9.4%) acute HFs, 167 (16%) cardiovascular events, and 418 (40%) all-cause deaths. There were no differences in mean ABC-stroke and ABC-bleeding scores in patients with/without MI (p = 0.367 and p = 0.286, respectively); both scores were higher in patients with acute HF, cardiovascular events, or death (all p < 0.05). Predictive performances for the ABC-stroke and ABC-bleeding scores were similar, ranging from “poor” for MI (c-indexes ∼0.54), “moderate” for acute HF and cardiovascular events (c-indexes ∼0.60 and ∼0.64, respectively), and “good” for all-cause mortality (c-indexes > 0.70). Clinical usefulness whether assessed by ABC-stroke or ABC-bleeding was similar for various primary endpoints. Conclusion In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict “sick” patients or poor prognosis overall.

A Novel ABC Score Predicts Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Who underwent Percutaneous Coronary Intervention

“…In addition, our ABC score is different from the previously published ABC-stroke and ABC-bleeding scores which were developed using age, biomarkers, and clinical history to predict outcomes in atrial fibrillation patients. 25 In Camelo-Castillo et al's study, both ABC-stroke and the ABCbleeding scores demonstrated a poor to moderate ability in predicting ischemic events (C-indexes: 0.54-0.64), but a good ability in predicting ACM (C-indexes > 0.70). Our ABC score only including three variables has strong ability to Fig.…”

Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation

“…Nevertheless, the clinical usefulness of biomarkers when they are evaluated alone may be only limited. In fact, a common criticism of biomarkers is their high variability and lack of specificity in different clinical settings [38][39][40]. However, an advantage of miRNAs compared to other biomarkers is their plasma stability, which makes them less likely to be altered due to acute conditions [9,41], even though results from miRNAs levels should be interpreted with caution and contextualized according to clinical risk factors.…”

Thrombosis and Haemostasis 2020 Editors' Choice Papers

“…Interestingly, several papers focused on the use of biomarkers for risk stratification in AF, and their nonspecific nature, being reflective of a sick patient or a sick heart. 28,29 The updated systematic review on the association of antiphosphatidylserine/prothrombin antibodies with the autoimmune disorder antiphospholipid syndrome, may help identifying antiphospholipid syndrome patients otherwise negative for current tests. 30 The relevance of clinical conclusions also relies on the strength of the technique used.…”